129 related articles for article (PubMed ID: 38164002)
1. Clinical Characteristics and Outcomes of Prolactinomas in Children and Adolescents: A Large Retrospective Cohort Study.
Yang Y; Ke X; Duan L; Yang H; Gong F; Pan H; Wang L; Zhu H
J Clin Endocrinol Metab; 2024 Jan; ():. PubMed ID: 38164002
[TBL] [Abstract][Full Text] [Related]
2. Clinical, Hormonal, and Neuroradiological Characteristics and Therapeutic Outcomes of Prolactinomas in Children and Adolescents at a Single Center.
Yang A; Cho SY; Park H; Kim MS; Kong DS; Shin HJ; Jin DK
Front Endocrinol (Lausanne); 2020; 11():527. PubMed ID: 32849307
[No Abstract] [Full Text] [Related]
3. Giant prolactinomas larger than 60 mm in size: a cohort of massive and aggressive prolactin-secreting pituitary adenomas.
Shimon I; Sosa E; Mendoza V; Greenman Y; Tirosh A; Espinosa E; Popovic V; Glezer A; Bronstein MD; Mercado M
Pituitary; 2016 Aug; 19(4):429-36. PubMed ID: 27138902
[TBL] [Abstract][Full Text] [Related]
4. Transnasal surgery for prolactin-secreting pituitary adenomas in childhood and adolescence.
Abe T; Lüdecke DK
Surg Neurol; 2002 Jun; 57(6):369-78; discussion 378-9. PubMed ID: 12176193
[TBL] [Abstract][Full Text] [Related]
5. Transsphenoidal microsurgical therapy of prolactinomas: initial outcomes and long-term results.
Tyrrell JB; Lamborn KR; Hannegan LT; Applebury CB; Wilson CB
Neurosurgery; 1999 Feb; 44(2):254-61; discussion 261-3. PubMed ID: 9932878
[TBL] [Abstract][Full Text] [Related]
6. The outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy.
Soule SG; Farhi J; Conway GS; Jacobs HS; Powell M
Clin Endocrinol (Oxf); 1996 Jun; 44(6):711-6. PubMed ID: 8759184
[TBL] [Abstract][Full Text] [Related]
7. Gender Differences in Patients with Prolactinoma: Single-center Ukrainian Experience.
Voznyak O; Zinkevych I; Lytvynenko A; Hryniv N; Ilyuk R; Kobyliak N
Rev Recent Clin Trials; 2024 Mar; ():. PubMed ID: 38561622
[TBL] [Abstract][Full Text] [Related]
8. Retrospective analysis of 52 patients with prolactinomas following endoscopic endonasal transsphenoidal surgery.
Han YL; Chen DM; Zhang C; Pan M; Yang XP; Wu YG
Medicine (Baltimore); 2018 Nov; 97(45):e13198. PubMed ID: 30407358
[TBL] [Abstract][Full Text] [Related]
9. Women with prolactinomas presented at the postmenopausal period.
Shimon I; Bronstein MD; Shapiro J; Tsvetov G; Benbassat C; Barkan A
Endocrine; 2014 Dec; 47(3):889-94. PubMed ID: 24711223
[TBL] [Abstract][Full Text] [Related]
10. Resistant prolactinomas: a case series of 26 patients.
Eshkoli T; Fraenkel M; Zaid D; Cohen D; Yoel U; Tsvetov G; Gorshtein A; Goldbart A; Greenman Y; Shimon I
Endocrine; 2022 Aug; 77(2):349-356. PubMed ID: 35604631
[TBL] [Abstract][Full Text] [Related]
11. Five years follow-up of invasive prolactinomas with special reference to the control of cavernous sinus invasion.
Wu ZB; Su ZP; Wu JS; Zheng WM; Zhuge QC; Zhong M
Pituitary; 2008; 11(1):63-70. PubMed ID: 17917811
[TBL] [Abstract][Full Text] [Related]
12. Bromocriptine treatment of invasive giant prolactinomas involving the cavernous sinus: results of a long-term follow up.
Wu ZB; Yu CJ; Su ZP; Zhuge QC; Wu JS; Zheng WM
J Neurosurg; 2006 Jan; 104(1):54-61. PubMed ID: 16509147
[TBL] [Abstract][Full Text] [Related]
13. Surgery is a safe, effective first-line treatment modality for noninvasive prolactinomas.
Park JY; Choi W; Hong AR; Yoon JH; Kim HK; Jang WY; Jung S; Kang HC
Pituitary; 2021 Dec; 24(6):955-963. PubMed ID: 34189717
[TBL] [Abstract][Full Text] [Related]
14. Long-term Follow-up of 84 Patients With Giant Prolactinomas-A Swedish Nationwide Study.
Himonakos C; Burman P; Borg H; Dahlqvist P; Engström BE; Ekman B; Emilsson L; Olsson DS; Ragnarsson O; Wahlberg J; Åkerman AK; Höybye C; Berinder K
J Clin Endocrinol Metab; 2023 Nov; 108(12):e1506-e1514. PubMed ID: 37403202
[TBL] [Abstract][Full Text] [Related]
15. SURGICAL OUTCOMES OF PROLACTINOMAS IN RECENT ERA: RESULTS OF A HETEROGENOUS GROUP.
Donegan D; Atkinson JL; Jentoft M; Natt N; Nippoldt TB; Erickson B; Meyer F; Erickson D
Endocr Pract; 2017 Jan; 23(1):37-45. PubMed ID: 27682355
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients.
Primeau V; Raftopoulos C; Maiter D
Eur J Endocrinol; 2012 May; 166(5):779-86. PubMed ID: 22301915
[TBL] [Abstract][Full Text] [Related]
17. First-line surgery in prolactinomas: lessons from a long-term follow-up study in a tertiary referral center.
Andereggen L; Frey J; Andres RH; Luedi MM; El-Koussy M; Widmer HR; Beck J; Mariani L; Seiler RW; Christ E
J Endocrinol Invest; 2021 Dec; 44(12):2621-2633. PubMed ID: 33847973
[TBL] [Abstract][Full Text] [Related]
18. The role of endoscopic endonasal surgery in the management of prolactinomas based on their invasiveness into the cavernous sinus.
Abou-Al-Shaar H; Mallela AN; Patel A; Shariff RK; Shin SS; Choi PA; Faraji AH; Fazeli PK; Costacou T; Wang EW; Fernandez-Miranda JC; Snyderman CH; Gardner PA; Zenonos GA
Pituitary; 2022 Jun; 25(3):508-519. PubMed ID: 35467273
[TBL] [Abstract][Full Text] [Related]
19. T2-weighted magnetic resonance imaging characterization of prolactinomas and association with their response to dopamine agonists.
Burlacu MC; Maiter D; Duprez T; Delgrange E
Endocrine; 2019 Feb; 63(2):323-331. PubMed ID: 30267354
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of transsphenoidal surgery in dopamine agonist-resistant prolactinomas: a retrospective study.
Wei L; Wei X
Hormones (Athens); 2021 Dec; 20(4):745-752. PubMed ID: 34275094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
